Rémy Gressin

Centre National de la Recherche Scientifique — France

Medicine · Health Sciences

43h-index8.6kcitations258works2.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(194), Chronic Lymphocytic Leukemia Research(76), Viral-associated cancers and disorders(55), CNS Lymphoma Diagnosis and Treatment(55), CAR-T cell therapy research(33)

Publications256 total

Results of the primary end-point of the LOC-R01: A randomized phase II Study of lenalidomide and ibrutinib in association with rituximab-methotrexate procarbazine vincristin (R-MPV) as a targeted induction treatment for patients aged 18 to 65 with a newly diagnosed primary central nervous system lymphoma (PCNSL)
Blood·2025
Secondary-type acute myeloid leukemia is associated with a higher risk of invasive fungal infection during intensive induction therapy. a correlative study on the ALFA 0702 trial.
Blood·2025Open Access
Automatic Segmentation of Primary Central Nervous System Lymphoma at Clinical Routine Postcontrast T1-weighted MRI
Radiology Imaging Cancer·2025Open Access
254 | RITUXIMAB AND IBRUTINIB COMBINATION IN UNTREATED SMZL AND NMZL: LONG‐TERM OUTCOME AND THE IMPACT OF EARLY MINIMAL RESIDUAL DISEASE FROM THE IELSG47/MALIBU PHASE II STUDY
Hematological Oncology·2025Open Access
52 | RITUXIMAB AND IBRUTINIB COMBINATION IS SAFE AND EFFECTIVE IN UNTREATED EXTRANODAL MARGINAL ZONE LYMPHOMAS: FIRST ANALYSIS OF THE IELSG47/MALIBU PHASE II STUDY
Hematological Oncology·2025Open Access
598 | REDEFINING CLASSIFICATION ALGORITHM AND STAGING SYSTEM IN MARGINAL ZONE LYMPHOMA
Hematological Oncology·2025· 1 citedOpen Access
Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non‐Hodgkin lymphoma: Final analysis of a phase II trial from the <scp>LYSA</scp> group
British Journal of Haematology·2025· 1 citedOpen Access
Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study
Blood Cancer Journal·2025· 3 citedOpen Access
A low lymphocyte‐to‐monocyte ratio is independently associated with early relapse (POD24) in high tumour burden follicular lymphoma: A RELEVANCE subanalysis
British Journal of Haematology·2025· 1 citedOpen Access
BET inhibition revealed varying MYC dependency mechanisms independent of gene alterations in aggressive B-cell lymphomas
Clinical Epigenetics·2024· 2 citedOpen Access
High-dose chemotherapy with autologous haematopoietic stem cell transplantation in patients with isolated vitreoretinal lymphoma: a LOC network study
Bone Marrow Transplantation·2024· 3 citedOpen Access
Predictive Power of Early, Sequential Minimal Residual Disease and Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Monitoring in Young Patients with Mantle Cell Lymphoma in the Lyma Trial: A Lysa Study
Blood·2024Open Access
P20.17.B PRIMARY CEREBRAL T-CELL LYMPHOMAS DISPLAY AN ATYPICAL PRESENTATION: A LOC STUDY
Neuro-Oncology·2024Open Access
Real‐world data for marginal zone lymphoma patients in the French REALYSA cohort: The REALMA study
Hematological Oncology·2024· 2 citedOpen Access
Author response for "Real‐world data for marginal zone lymphoma patients in the French REALYSA cohort: The REALMA study"
2024
High-dose chemotherapy with autologous haematopoietic stem cell transplantation in patients with isolated vitreoretinal lymphoma: A LOC network study
2024Open Access
BET inhibition revealed varying MYC addiction mechanisms independent of gene alterations in aggressive B-cell lymphomas.
2024Open Access
Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study
The Lancet Haematology·2024· 25 citedOpen Access
Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma
Blood·2024· 10 citedOpen Access
IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma
Haematologica·2024· 3 citedOpen Access
page 1 of 13Next →

Frequent Co-authors

Emmanuel Gyan(23), Steven Le Gouill(16), Vincent Delwail(14), Gandhi Damaj(14), Sylvain Choquet(12), Roch Houot(12), T. Lamy(12), Carole Soussain(12), Olivier Tournilhac(11), Caroline Houillier(11), Khê Hoang‐Xuan(11), Krimo Bouabdallah(10), Olivier Casasnovas(10), Cécile Moluçon‐Chabrot(10), Hervé Ghesquières(10), Philippe Moreau(9), Éric Deconinck(9), Pierre Soubeyran(9), Olivier Chinot(9), Corinne Haïoun(8)